VIRACTA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.481 USD | -1.84% |
|
-16.78% | -15.61% |
| Jun. 12 | XOMA Receives $8.1 Million Milestone Related to Sale of Priority Review Voucher | MT |
| May. 30 | Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 136.2 | 55.77 | 22.02 | 18.89 | - | - |
| Enterprise Value (EV) 1 | 37.45 | 55.77 | 22.02 | 18.89 | 18.89 | 18.89 |
| P/E ratio | -1.01 x | -1.12 x | -0.43 x | -0.42 x | -0.42 x | -0.39 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 5.4 x | 0.62 x |
| EV / Revenue | - | - | - | - | 5.4 x | 0.62 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | -7,129,119 x | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 37,312 | 38,197 | 38,625 | 39,272 | - | - |
| Reference price 2 | 3.650 | 1.460 | 0.5700 | 0.4810 | 0.4810 | 0.4810 |
| Announcement Date | 3/16/22 | 3/13/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 3.5 | 30.32 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -12.06 | -127.8 | -50.59 | -50.69 | -66.81 | -84.2 | -76.27 |
| Operating Margin | - | - | - | - | - | -2,405.86% | -251.54% |
| Earnings before Tax (EBT) 1 | - | -114.8 | -49.2 | -51.06 | -63.97 | -81.36 | -71.39 |
| Net income 1 | - | -114.8 | -49.2 | -51.06 | -62.54 | -89.18 | -88.4 |
| Net margin | - | - | - | - | - | -2,548.07% | -291.53% |
| EPS 2 | -5.750 | -3.600 | -1.300 | -1.320 | -1.155 | -1.155 | -1.225 |
| Free Cash Flow | - | -19.1 | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 12/22/20 | 3/16/22 | 3/13/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -11.32 | -10.43 | -10.5 | -18.08 | -11.57 | -12.21 | -12.45 | -12.48 | -13.56 | -13.88 | -15.35 | -17.9 | -19.68 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -11.45 | -10.55 | -10.58 | -17.74 | -10.33 | -12.21 | -12.48 | -12.6 | -13.76 | -9.141 | -15.99 | -18.53 | -20.31 |
| Net income 1 | -11.45 | -10.55 | -10.58 | -17.74 | -10.33 | -12.21 | -12.48 | -12.6 | -13.76 | -9.141 | -15.61 | -17.52 | -20.31 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.3100 | -0.2800 | -0.2800 | -0.4700 | -0.2700 | -0.3200 | -0.3200 | -0.3300 | -0.3500 | -0.2300 | -0.3633 | -0.2967 | -0.3200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/22 | 5/10/22 | 8/9/22 | 11/10/22 | 3/13/23 | 5/8/23 | 8/14/23 | 11/9/23 | 3/7/24 | 5/9/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | 98.7 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | -19.1 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | 0.25 | - | 0.14 | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/16/22 | 3/13/23 | 3/7/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.481
USD
Average target price
5
USD
Spread / Average Target
+939.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.61% | 18.89M | |
| +16.59% | 44.44B | |
| +42.55% | 40.03B | |
| -10.62% | 37.68B | |
| +29.92% | 31.46B | |
| -9.23% | 27.29B | |
| +12.34% | 26.29B | |
| +41.53% | 13.8B | |
| +31.49% | 12.46B | |
| -7.40% | 11.26B |
- Stock Market
- Equities
- VIRX Stock
- Financials Viracta Therapeutics, Inc.
